Hyalgan

Hyalgan is a prescription intra‑articular injection containing sodium hyaluronate, a form of hyaluronic acid, supplied as a sterile solution for joint administration. The product is marketed in the European Union and classified as a viscosupplement. It is administered by a healthcare professional directly into the affected knee joint to help restore viscoelastic properties and support joint function. The treatment is intended for patients with symptomatic osteoarthritis.

Hyalgan is indicated for the symptomatic treatment of osteoarthritis of the knee when other conservative measures have not provided adequate relief.

- Management of knee osteoarthritis pain in adults. - Adjunct to physical therapy and exercise programs. - Use in patients who are unsuitable for oral NSAIDs. - May be considered when intra‑articular corticosteroids are contraindicated. - Intended for single‑joint administration, typically a series of weekly injections.

Adverse reactions to Hyalgan are generally related to the injection procedure and the product itself. Reported events range from mild, transient symptoms to rare serious complications.

Common: - Mild pain or tenderness at the injection site lasting a few hours. - Local swelling or joint effusion that resolves within a few days. - Warmth or mild erythema around the injection area without systemic signs. - Temporary stiffness or reduced range of motion that improves with activity. - Transient headache or flu‑like symptoms such as low‑grade fever.

Serious: - Acute septic arthritis requiring antibiotics or surgical drainage. - Allergic reaction ranging from urticaria or rash to anaphylactic shock. - Persistent severe synovitis with marked swelling and pain. - Joint hemorrhage (hemarthrosis), particularly in patients receiving anticoagulant therapy. - Nerve injury leading to prolonged numbness, tingling, or weakness in the leg.

Before using Hyalgan, clinicians should evaluate patient history and joint condition to minimize risks and ensure appropriate use.

- Confirm diagnosis of knee osteoarthritis and consider alternative therapies first. - Avoid injection in infected or inflamed joints, or in the presence of active skin disease over the injection site. - Use caution in patients with a history of hypersensitivity to hyaluronic acid preparations. - Assess bleeding risk; postpone treatment in patients on anticoagulants or with coagulation disorders. - Monitor for signs of infection or severe inflammation after each injection. - Do not use in pregnant or nursing women unless benefits outweigh potential risks.

Hyalgan may interact with other agents that affect joint health or bleeding risk, and certain medications can influence the safety of intra‑articular injections.

Avoid: - Concurrent intra‑articular corticosteroids or other viscosupplements in the same joint. - Administration during an active joint infection or systemic infection.

Use with caution: - Anticoagulant or antiplatelet therapy (e.g., warfarin, aspirin, clopidogrel) due to increased bleeding risk. - Systemic non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask signs of joint infection. - Disease‑modifying osteoarthritis drugs that could alter joint environment. - Immunosuppressive agents that may predispose to infection.